Brokerages Expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to Announce $0.12 Earnings Per Share

Share on StockTwits

Wall Street brokerages forecast that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will post earnings per share of $0.12 for the current quarter, according to Zacks. Three analysts have made estimates for Vanda Pharmaceuticals’ earnings. The highest EPS estimate is $0.20 and the lowest is $0.04. Vanda Pharmaceuticals posted earnings per share of $0.26 in the same quarter last year, which suggests a negative year-over-year growth rate of 53.8%. The company is scheduled to announce its next quarterly earnings results on Wednesday, February 12th.

On average, analysts expect that Vanda Pharmaceuticals will report full-year earnings of $2.16 per share for the current fiscal year, with EPS estimates ranging from $2.08 to $2.24. For the next financial year, analysts expect that the firm will report earnings of $0.98 per share, with EPS estimates ranging from $0.13 to $1.83. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $1.77. Vanda Pharmaceuticals had a net margin of 55.49% and a return on equity of 38.90%. The company had revenue of $59.49 million during the quarter, compared to analysts’ expectations of $58.33 million. During the same quarter in the prior year, the company posted $0.13 EPS. The business’s revenue was up 21.1% on a year-over-year basis.

Several brokerages recently commented on VNDA. ValuEngine lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 8th. Stifel Nicolaus reissued a “hold” rating and set a $17.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, November 7th. Citigroup downgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $19.00 target price on the stock. in a research note on Thursday, November 7th. BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 27th. Finally, Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. Two equities research analysts have rated the stock with a sell rating and five have given a hold rating to the company’s stock. Vanda Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $19.00.

Shares of VNDA stock traded up $0.01 during trading hours on Wednesday, hitting $16.41. The company had a trading volume of 291,283 shares, compared to its average volume of 540,622. Vanda Pharmaceuticals has a 12 month low of $11.83 and a 12 month high of $31.30. The firm’s fifty day moving average is $16.55 and its 200 day moving average is $14.55. The firm has a market capitalization of $875.31 million, a price-to-earnings ratio of 34.19 and a beta of 0.35.

Several hedge funds and other institutional investors have recently made changes to their positions in VNDA. North Star Investment Management Corp. acquired a new position in shares of Vanda Pharmaceuticals during the third quarter worth approximately $66,000. Meeder Asset Management Inc. raised its position in Vanda Pharmaceuticals by 1,638.3% in the 3rd quarter. Meeder Asset Management Inc. now owns 5,215 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 4,915 shares during the last quarter. Pacer Advisors Inc. bought a new position in Vanda Pharmaceuticals in the 2nd quarter worth approximately $138,000. Clarus Wealth Advisors acquired a new position in Vanda Pharmaceuticals during the 3rd quarter worth $133,000. Finally, Zebra Capital Management LLC acquired a new position in Vanda Pharmaceuticals during the 2nd quarter worth $170,000. 99.29% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Featured Article: How to Invest in an Index Fund

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with's FREE daily email newsletter.